Enliven Therapeutics, Inc.
ELVN
$36.89
$0.782.17%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.14M | 33.80M | 26.93M | 25.87M | 24.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 115.79M | 119.66M | 112.27M | 114.24M | 110.26M |
| Operating Income | -115.79M | -119.66M | -112.27M | -114.24M | -110.26M |
| Income Before Tax | -98.78M | -103.69M | -97.21M | -100.22M | -94.60M |
| Income Tax Expenses | -- | -- | 0.00 | 0.00 | 232.00K |
| Earnings from Continuing Operations | -98.78 | -103.69 | -97.21 | -100.22 | -94.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -98.78M | -103.69M | -97.21M | -100.22M | -94.83M |
| EBIT | -115.79M | -119.66M | -112.27M | -114.24M | -110.26M |
| EBITDA | -115.59M | -119.40M | -111.97M | -113.93M | -109.95M |
| EPS Basic | -1.66 | -1.86 | -1.85 | -2.00 | -1.93 |
| Normalized Basic EPS | -1.04 | -1.16 | -1.15 | -1.25 | -1.21 |
| EPS Diluted | -1.66 | -1.86 | -1.85 | -2.00 | -1.93 |
| Normalized Diluted EPS | -1.04 | -1.16 | -1.15 | -1.25 | -1.21 |
| Average Basic Shares Outstanding | 239.21M | 226.46M | 214.11M | 200.28M | 196.25M |
| Average Diluted Shares Outstanding | 239.21M | 226.46M | 214.11M | 200.28M | 196.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |